机译:一种新的非激动剂C-Met抗体抗体药物缀合物,其具有优异的C-Met酪氨酸激酶抑制剂在C-Met扩增和非扩增癌症中的效力
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
Tanabe Res Labs USA Inc Res Dept 4540 Towne Ctr Court San Diego CA 92121 USA;
c-Met; ADC (antibody drug conjugate); MMAF; gastric cancer; non-agonistic antibody; lung cancer;
机译:一种新的非激动剂C-Met抗体抗体药物缀合物,其具有优异的C-Met酪氨酸激酶抑制剂在C-Met扩增和非扩增癌症中的效力
机译:酪氨酸激酶抑制剂耐药的中国非小细胞肺癌表皮生长因子受体T790M突变和c-MET扩增的临床病理和分子特征
机译:C-Met酪氨酸激酶抑制剂和CDK 4/6抑制剂组合药物治疗的单一口服剂量急性和亚急性毒性
机译:在Silico HIS鉴定,药物重新扫描,药代动力学和癌症治疗中C-Met激酶抑制剂的毒性预测
机译:硒蛋白W通过调节受体泛素化抑制c-Met癌基因。
机译:一种新的非激动剂C-Met抗体抗体药物缀合物其具有优异的C-Met酪氨酸激酶抑制剂在C-Met扩增和非扩增癌症中的效力
机译:雷帕霉素抑制剂的多个受体酪氨酸激酶抑制剂和哺乳动物靶标的组合通过C-MET抑制来克服肺癌细胞系中的欧洛替尼抗性